Colesevelam for Children With Type 2 Diabetes

Inclusion Criteria: * Diagnosis of type 2 diabetes mellitus, as defined by the American Diabetes Association; * Written informed consent of study participation * Males and females aged 10 to 17 years, inclusive, at randomization (randomization must occur before 18th birthday); * HbA1c at screening between 7.0% and 10.0%, inclusive; * Fasting C-peptide \>0.6 ng/mL; and * Anti-diabetic treatment at screening: * Treatment-naïve or untreated; OR * On metformin monotherapy: Metformin monotherapy has been initiated prior to screening. Exclusion Criteria: * Fasting plasma glucose \>270 mg/dL; * Diagnosis of type 1 diabetes; * History of more than one episode of ketoacidosis after the initial diagnosis of type 2 diabetes mellitus; * Clinical laboratory assessments/evaluations, eg. autoimmune markers, aminotransferases, triglycerides, creatinine clearance, and Hb variants, that are not within the protocol-defined parameters * Systolic blood pressure ≥150 mmHg or diastolic blood pressure ≥95 mmHg * Use of medications not allowed by protocol-defined parameters, eg. insulin or any medication that affects insulin sensitivity or secretion, growth hormones/somatotropin, or anabolic steroids * Genetic syndrome or disorder known to affect glucose * Participation in a weight loss program or another interventional research study within 60 days; * Female participants who are lactating, pregnant, or plan to become pregnant within 1 year of screening; * Female participants who are sexually active and unwilling to use appropriate contraception for the duration of the study; * History of bowel obstruction; * Other significant organ system illness or condition (including psychiatric or developmental disorder) that, in the opinion of the Investigator, would prevent full participation